L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension

Blood Pressure

Volumn 21, Issue 6, 2012, Pages 367-371

  Ogura, Chika ^a   Ono, Koh ^a   Miyamoto, Shoichi ^b   Ikai, Akiko ^a   Mitani, Satoko ^a   Sugimoto, Naozo ^a   Tanaka, Shiro ^c   Fujita, Masatoshi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kitano Hospital   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Autonomic nerve activity; Calcium channel blocker; Heart rate variability; Hypertension; Norepinephrine

Indexed keywords

AMLODIPINE; CILNIDIPINE; EFONIDIPINE; NORADRENALIN;

AGED; ARTICLE; AUTONOMIC NERVE; BLOOD PRESSURE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; EVALUATION; FEMALE; HEART HEMODYNAMICS; HEART NERVE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; NERVE CONDUCTION; NORADRENALIN BLOOD LEVEL; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE RATE; SPECTROSCOPY; SYMPATHETIC NERVE; VAGUS NERVE;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; CROSS-OVER STUDIES; DIHYDROPYRIDINES; FEMALE; HEART; HEART CONDUCTION SYSTEM; HEMODYNAMICS; HUMANS; HYPERTENSION; MALE; NITROPHENOLS; NOREPINEPHRINE; ORGANOPHOSPHORUS COMPOUNDS; PROSPECTIVE STUDIES; SYMPATHETIC NERVOUS SYSTEM;

EID: 84870675675     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2012.694200     Document Type: Article

References (20)

1. Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens. 2007;25: 169-175.
2. Nakano A, Lee JD, Takeishi Y, Hirai T, Kato M, Kinugawa T, et al. Comparative effects of valsartan and amlodipine on cardiac autonomic nervous activity in hypertensive patients. Int J Angiol. 2006;15: 179-182.
3. Harada K, Nomura M, Nishikado A, Uehara K, Nakaya Y, Ito S. Clinical efficacy of hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. Circ J. 2003;67: 139-145.
4. Kinoshita H, Kuwahara K, Takano M, Arai Y, Kuwabara Y, Yasuno S, et al. T-type Ca 2+ channel blockade prevents sudden death in mice with heart failure. Circulation. 2009; 120: 743-752.
5. Nakano N, Ishimitsu T, Takahashi T, Inada H, Okamura A, Ohba S, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin - angiotensin - aldosterone system in chronic hemodialysis patients. Int Heart J. 2010;51: 188-192.
6. Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ, et al. Dominant role of N-type Ca 2+ channels in evoked release of norepinephrine from sympathetic neurons. Science. 1988;239: 57-61.
7. Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca++ -channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 1997;280: 1184-1191.
8. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, et al. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension. 1999;33: 1447-1452.
9. Kosaka T, Nakagawa M, Ishida M, Iino K, Watanabe H, Hasegawa H, et al. Cardioprotective effect of an L/N-type calcium channel blocker in patients with hypertensive heart disease. J Cardiol. 2009;54: 262-272.
10. Konoshita T, Makino Y, Kimura T, Fujii M, Wakahara S, Arakawa K, et al. Genomic Disease Outcome Consortium Study Investigators. A new-generation N/L-type calcium channel blocker leads to less activation of the renin - angiotensin system compared with conventional L type calcium channel blocker. J Hypertens. 2010;28: 2156-2160.
11. Fujita M, Miyamoto S, Sekiguchi H, Eiho S, Sasayama S. Effects of posture on sympathetic nervous modulation in patients with chronic heart failure. Lancet. 2000;356: 1822-1823.
12. Miyamoto S, Fujita M, Sekiguchi H, Okano Y, Nagaya N, Ueda K, et al. Effects of posture on cardiac autonomic nervous activity in patients with congestive heart failure. J Am Coll Cardiol. 2001;37: 1788-1793.
13. Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. J Am Coll Cardiol. 1993;21: 729-736.
14. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311: 819-823.
15. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet. 1978;311: 795-797.
16. Huikuri HV, Niemel ä MJ, Ojala S, Rantala A, Ik äh eimo MJ, Airaksinen KE. Circadian rhythms of frequency domain measures of heart rate variability in healthy subjects and patients with coronary artery disease. Effects of arousal and upright posture. Circulation. 1994;90: 121-126.
17. Turton MB, Deegan T. Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta. 1974;55: 389-397.
18. Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P. Measurement of total and organ-specific norepinephrine kinetics in humans. Am J Physiol. 1984;247: E21 - E28.
19. Grassi G, Seravalle G, Turri C, Bolla G, Mancia G. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003,41: 558-562.
20. Senn S. Baseline balance and valid statistical analysis: common misunderstandings. Appl Clin Trials. 2005,14: 24-27.